Analytical Performance of the AMDI™ Fast PCR Mini Respiratory Panel

Louis Geller, Alyssa Fiore, Liza Perez, Corinne Minzer, Yujia Liu, Estibaliz Alvarado, Nicholas Casarez, Brenda Martinez, Justin Nako, Gabriel Rodriguez, Yvette Arroyo, Nicholas E. Johnsen, Christopher A. Ross, Francesca Foltz, Regina Martin, Régis Peytavi, Aravind Srinivasan

Abstract

Influenza A, Influenza B, SARS-CoV-2, and Respiratory Syncytial Virus (RSV) remain significant public health challenges. Rapid identification of these pathogens is critical for clinical management and infection control. The AMDI™ Fast PCR Mini Respiratory Panel (MRP) integrates rapid sample preparation with real-time RT-PCR to detect these four viruses from anterior nasal swab (ANS) specimens in under 10 minutes. This study establishes the analytical performance of the Fast PCR MRP, demonstrating a limit of detection (LoD) of 250 copies/mL for Flu A and RSV, and 500 copies/mL for Flu B and SARS-CoV-2. Multi-site reproducibility studies showed >98% agreement for weak positive samples. The system exhibited 100% analytical reactivity across 43 strains and no cross-reactivity with 40 common respiratory organisms.

Introduction

In respiratory diagnostics, there is a persistent gap between rapid antigen tests and laboratory-based molecular assays. Antigen tests offer speed (results in minutes) but often lack the sensitivity required to detect low viral loads early in an infection. Conversely, gold-standard Nucleic Acid Amplification Tests (NAATs) like RT-PCR provide high sensitivity but typically require centralized laboratory infrastructure and hours of processing time.

The AMDI™ Fast PCR system addresses this "unmet need" by providing a point-of-care (POC) molecular test that matches the speed of antigen tests while maintaining the sensitivity of high-complexity NAATs. This paper evaluates the analytical performance characteristics of the Fast PCR MRP to validate its utility in clinical settings.

Methodology

The Fast PCR MRP utilizes a multiplex real-time RT-PCR platform. The core innovation is a hyperbaric heating method for sample processing. This technique employs pressure and heat to rapidly lyse microorganisms and neutralize PCR inhibitors, eliminating the need for lengthy chemical extraction steps.

Fast PCR Testing Workflow and Result Interface

The workflow is designed for simplicity at the point of care, involving four primary steps: drawing the sample from the vial, loading the MRP disc, placing the disc into the operating module, and starting the run. Results are delivered to a digital interface in approximately 10 minutes.

Analytical Validation Protocol

The researchers conducted a series of rigorous tests:

  • Limit of Detection (LoD): Established using serial dilutions of quantified viral stocks (Flu A, Flu B, RSV, and SARS-CoV-2) in a negative nasal swab matrix.
  • Reproducibility: A multi-site study was conducted at three clinical locations using "untrained operators" to simulate real-world POC environments.
  • Inclusivity and Specificity: The panel was tested against 43 different viral strains ("wet-testing") and supplemented by in silico analysis of thousands of sequences from the GISAID and NCBI Virus databases.
  • Interference Testing: 15 common endogenous and exogenous substances (e.g., blood, mucus, nasal sprays, and antivirals) were evaluated for potential inhibitory effects.

Results

Sensitivity and Limit of Detection

The Fast PCR MRP achieved high sensitivity across all targets. The LoD was determined to be 250 copies/mL for Flu A and RSV, and 500 copies/mL for Flu B and SARS-CoV-2. These levels are significantly lower than typical antigen tests, which often require $10^4$ to $10^6$ copies/mL for detection.

Reproducibility and Agreement

The system demonstrated exceptional consistency across different operators and sites. In the reproducibility study, samples at 2x LoD (weak positives) returned positive results at a rate of at least 98.2%.

Reproducibility and Agreement Data at Various Concentrations

As shown in the table above, agreement reached 100% for most analytes at 5x LoD. Negative samples also showed high specificity, with at least 99.3% returning negative results.

Analytical Specificity and Inclusivity

The assay showed 100% analytical reactivity to all 43 strains tested in the lab. In silico analysis predicted >98% inclusivity for all targets, including 99.99% coverage for SARS-CoV-2 variants. Furthermore, no cross-reactivity was observed with 40 off-panel organisms, including other human coronaviruses, MERS-CoV, and common bacteria like S. pneumoniae.

Multiplex Robustness

A "quadspike" study was performed to evaluate competitive inhibition. When all four viruses were present simultaneously at their respective LoDs, the system detected every target with 100% positivity. This confirms that the multiplex design can effectively handle co-infections without signal interference.

Discussion

The transition from a 60-minute laboratory PCR to a 10-minute POC test is a significant engineering milestone. By combining hyperbaric lysis with optimized microfluidic metering, the Fast PCR MRP removes the primary bottlenecks of molecular diagnostics. The high reproducibility among untrained operators suggests that the automated "sample-to-answer" workflow is robust against human error, a critical requirement for CLIA-waived environments.

Limitations

While the analytical results are compelling, they were obtained under controlled laboratory conditions using contrived samples. Although the authors mention a clinical study with 1,906 patient samples, the data presented here does not fully capture the biological variability of "real-world" clinical specimens. Additionally, while in silico monitoring is effective, it cannot perfectly predict performance against future, rapidly evolving viral strains.

Conclusion

The AMDI™ Fast PCR Mini Respiratory Panel delivers laboratory-grade analytical performance at the point of care. With a turnaround time of 10 minutes and high sensitivity for Flu A, Flu B, RSV, and SARS-CoV-2, it provides a viable solution for rapid, accurate respiratory screening in decentralized settings.

Summary updated

Abstract

Abstract Influenza A, Influenza B, SARS-CoV-2, Respiratory Syncytial Virus and other respiratory pathogens are an ongoing public health concern. The ability to rapidly identify these viruses early in infection is essential for effective treatment and outbreak control. The AMDI™ Fast PCR Mini Respiratory Panel (MRP) incorporates sample preparation and real-time RT-PCR for detection of Flu A, Flu B, SARS-CoV-2 and RSV from anterior nasal swab (ANS) specimens in less than 10 minutes at the point of care. We established the analytical performance characteristics of the Fast PCR MRP and determined that the limit of detection (LoD) is 250 copies/mL for Flu A and RSV, and 500 copies/mL for Flu B and SARS-CoV-2. In a reproducibility study at 3 clinical sites, there was at least 98.2% positivity for each target for a weak positive (2x LoD) sample, at least 99.6% positivity for a moderate positive (5x LoD) sample and the negative sample returned a negative result for at least 99.3% of the tests. Fast PCR MRP had 100% analytical reactivity to all strains tested (23 Flu A, 6 Flu B, 8 SARS-CoV-2 and 6 RSV) and at least 98% predicted inclusivity from in silico analysis. There was no cross-reactivity to 40 viruses, bacteria and fungi, nor interference for 15 endogenous and exogenous substances in ANS matrix. The Fast PCR MRP delivers excellent analytical performance comparable to high complexity laboratory assays, at the point of care.
BibTeX
@misc{geller2025analytical,
  author = {Louis Geller and Alyssa Fiore and Liza Perez and Corinne Minzer and Yujia Liu and Estibaliz Alvarado and Nicholas Casarez and Brenda Martinez and Justin Nako and Gabriel Rodriguez and Yvette Arroyo and Nicholas E. Johnsen and Christopher A. Ross and Francesca Foltz and Regina Martin and Régis Peytavi and Aravind Srinivasan},
  title = {{Analytical Performance of the AMDI™ Fast PCR Mini Respiratory Panel}},
  year = {2025},
  doi = {10.64898/2025.12.22.25342853},
  howpublished = {medRxiv},
}
Figure